期刊文献+

食管癌组织表皮生长因子受体Ⅲ型突变体表达及其意义的探讨 被引量:1

Expression and significance of epidermal growth factor receptor variant Ⅲ in human esophageal carcinoma tissues
原文传递
导出
摘要 目的:检测表皮生长因子受体Ⅲ型突变体(EGFRvⅢ)在食管癌组织中的表达,探讨其与食管癌发生、发展的关系。方法:采用免疫组化和蛋白质印迹实验检测EGFRvⅢ在66例人食管癌组织的表达情况,评价EGFRvⅢ表达在食管癌患者的性别、年龄分布、肿瘤大小、生长方式、TNM分期和淋巴结转移等临床病理参数的表达分布情况。结果:免疫组化结果显示EGFRvⅢ主要分布于胞膜及胞质内,在肿瘤及正常组织表达的平均净灰度值分别为22.46±4.21和5.54±3.01,两者相比差异有统计学意义,t=6.701,P=0.001。蛋白质印迹实验结果显示,EGFRvⅢ在肿瘤及瘤旁正常组织中表达的平均净灰度值分别为0.828±0.15和0.083±0.049,两者相比差异有统计学意义,t=9.362,P=0.000。两种检验方法均显示,不同性别、年龄、肿瘤大小、生长方式组间EGFRvⅢ表达,差异无统计学意义(P>0.05),TNM分期、淋巴结转移和病理分级中EGFRvⅢ表达差异均有统计学意义,P<0.05。EGFRvⅢ在两种实验方法的一致性检验(r=0.917,P<0.001),提示两种方法结果一致性好。结论:EGFRvⅢ可能参与食管癌发生,并在食管癌的侵袭和转移中起重要作用。 OBJECTIVE: To detect the expression and significance of epidermal growth factor receptor variant Ⅲ (EGFRvⅢ) in the genesis and development of human esopha geaI carcinoma. METHODS: Imrnunohistochemistry and Western-blot analysis were used to semiquantitatively detect the ex pression of EGFRvⅢ protein in 66 human esophageal carcino ma cases and the relationship between various clinicopathologic factors and EGFRv Ⅲ protein was analyzed. RESULTS: The average gray scale values of esophageal carcinoma and normal tissues by immunohistochemistry were 22.46 ± 4.21 and 5.54 ± 3.01 respectively, which showed a significant difference (t=6.701, P=0.001). The average gray scale values between them by Western blot were 0. 828±0. 15 and 0. 083±0. 049 respectively, which showed a significant difference (t=9. 362, P〈 0. 000). The significant differences were observed in TNM stage, lymph node metastasis and classification (P〈 0.05) , but no significant differences were found in sex, age, tumor size and growing type (P〉0.05). The consistency analysis between immunohistochemistry and Western blot showed the consistency coefficient (r=0.917, P〈0.001), suggesting a good consistency. CONCLUSIONS: Human esophageal carci noma tissues express EGFRvⅢ. EGFRvⅢ may play an important role in the genesis and development of human esophageal carcinoma.
出处 《中华肿瘤防治杂志》 CAS 2009年第23期1821-1824,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(30600744 30770619) 教育部博士点基金(20060698049)
关键词 表皮生长因子 食管肿瘤/病理学 免疫组织化学 epidermal growth factor esophageal neoplasms/pathology immunohistochemistry
  • 相关文献

参考文献8

  • 1Yan X, Lin Y, Yang D,et al. A novel anti-CD146 monoelonal antibody, AA98, inhibits angiogenesis and tumor growth[J]. Blood, 2003, 102(1) :184-189.
  • 2段小艺,王健生,张明鑫,夏鹏.人肾透明细胞癌中EGFRvⅢ的表达及意义[J].西安交通大学学报(医学版),2008,29(4):441-442. 被引量:6
  • 3赵荫农,何妮,欧超,曹骥,陈军,刘剑勇,袁卫平.乳腺肿瘤组织中EGFR与EGFRv Ⅲ的表达及临床意义[J].中华肿瘤防治杂志,2007,14(3):185-188. 被引量:5
  • 4欧超,吴飞翔,罗元,曹骥,赵荫农,袁卫平,李瑗,苏建家.表皮生长因子受体Ⅲ型突变体在肝细胞癌中的表达及意义[J].癌症,2005,24(2):166-169. 被引量:19
  • 5Moscatello D K, Montgomery R B, Sundareshan P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor[J]. Oncogene, 1996, 13(1) :85-96.
  • 6Pawlowski V, Revillion F, Hebbar M, et al. Prognostic value of the type Ⅰ growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay[J]. Clin Cancer Res, 2000, 6(11) :4217-4225.
  • 7Okamoto I, Kenyon L C, Emlet D R, et al. Expression of constitutively activated EGFRvⅠ in non-small cell lung cancer[J]. Cancer Sci,2003, 94(1):50 -56.
  • 8Damstrup L, Wandahl P M, Bastholm L, et al. Epidermal growth factor receptor mutation type Ⅰ transfected into a small cell lung cancer cell Line is predominantly localized at the cell surface and enhances the malignanl phenotype[J]. Int J Cancer, 2002, 97(1):7-14.

二级参考文献32

  • 1欧超,吴飞翔,罗元,曹骥,赵荫农,袁卫平,李瑗,苏建家.表皮生长因子受体Ⅲ型突变体在肝细胞癌中的表达及意义[J].癌症,2005,24(2):166-169. 被引量:19
  • 2Shirakata Y, Komurasaki T, Toyoda H, et al. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes [J]. J Biol Chem, 2000,275 ( 8 ) : 5748-5753.
  • 3Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme [ J ]. Cancer Res, 2003,63 (20) : 6962-6970.
  • 4Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the v Ⅲ mutation of human epidermal growth factor receptor [J]. Tumour Biol, 2002,23(2) :61-69.
  • 5Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy [J]. Curr Cancer Drug Targets, 2002,2(2):91-102.
  • 6Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion [J]. Cancer Res, 2002,62(12) :3335-3339.
  • 7Luo X, Gong X, Tang CK. Suppression of EGFRv Ⅲ-mediatedproliferation and tumorigenesis of breast cancer cells by ribozyme [J]. Int J Cancer, 2003,104(6) :716-721.
  • 8Lavictoire SJ, Parolin DA, Klimowicz AC, et al. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRv Ⅲ [J]. J Biol Chem, 2003,278(7):5292-5299.
  • 9Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRv Ⅲ in non-small cell lung cancer[J]. Cancer Sci, 2003,94( 1 ) :50-56.
  • 10Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours [J]. Cancer Treat Rev, 2004,30(1):1-17.

共引文献24

同被引文献15

  • 1Lofdahl HE, Lane A, Lu Y, et al. Increased population prevalence of reflux and obesity in the United Kingdom compared with Swe- dena potential explanation for the difference in incidence of e- sophageal adenocarcinoma [J]. Eur J Gastroenterol Hepatol, 2011,23(2) :128-132.
  • 2Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer:o- rient to occident. Effects of chronology, geography and ethnicity[J]. J Gastroenterol Hepatol,2009,24(5):729 -735.
  • 3Neumann H, Monkemiiller K, Vieth M, et al. Chemoprevention of adenocarcinoma associated with Barrett' s esophagus., potential options[J]. Dig Dis,2009,27(1) :18-23.
  • 4Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in re- sected esophageal adenocarcinoma[J]. J Gastrointest Surg, 2004, 8(4) :448-453.
  • 5Pinto C, DiFabio,Barone C,et al. Phase H study of eetuximab in combi- nation with cisplatin and docetaxel in patients with untreated advanced gastric or gastrooesophageal junction adenocarcinoma(DOCETLlX stud- y)[J]. Br J Cancer,2009,101(8) :1261-1268.
  • 6Moinard C, Cynober L, de Bandt JP. Polyamine metabolism and implications in human diseases[J].Clinical Nutrition, 2005,24(2):184-197.
  • 7Pegg AE. Mammalian polyamine metabolism and function[J]. IUBMB Life,2009,61(9) :880-894.
  • 8Brabender J, Lord RV,Danenberg KD, et al. Up regulation of or- nithine decarboxylase mRNA expression in Barrett' s esophagus and Barrett's associated adenocarcinoma[J]. J Gastroinest Surg, 2001,5(2) : 174-181.
  • 9Miranda KC, Joseph SR, Yap AS, et al. Contextual binding of p120ctn to E-cad at the basolateral plasma membrane in polar- ized epithelia[J]. J Biol Chem,2003,278(44) :43480-43483.
  • 10Falkenback D,Nilbert M,Oberg S,et al. Prognostic value of cell adhesion in esophageal adenocarcinomas [J ]. Dis Esophagus, 2008,21(2) :97.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部